StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Travere Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -6.8%. For fiscal 2026 it was -12.8%, against -138.9% the year before. The highest annual figure on record is -12.8% in fiscal 2026.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2026Dec 31, 2025-12.8%+126.1
FY2025Dec 31, 2024-138.9%+128.4
FY2024Dec 31, 2023-267.2%+24.9
FY2023Dec 31, 2022-292.2%−140.9
FY2022Dec 31, 2021-151.3%−62.4
FY2021Dec 31, 2020-88.8%−10.5
FY2020Dec 31, 2019-78.3%−29.6
FY2019Dec 31, 2018-48.7%−14.0
FY2018Dec 31, 2017-34.7%+8.9
FY2017Dec 31, 2016-43.6%+7.2
FY2016Dec 31, 2015-50.8%+232.2
FY2015Dec 31, 2014-283.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2027Jun 30, 20262.3%+13.4
Q1 FY2027Mar 31, 2026-29.0%+23.2
Q4 FY2026Dec 31, 2025-25.0%+56.2
Q3 FY2026Sep 30, 202515.1%+104.4
Q2 FY2026Jun 30, 2025-11.1%+114.1
Q1 FY2026Mar 31, 2025-52.2%+284.3
Q4 FY2025Dec 31, 2024-81.2%+127.9
Q3 FY2025Sep 30, 2024-89.3%+160.3
Q2 FY2025Jun 30, 2024-125.1%+197.8
Q1 FY2025Mar 31, 2024-336.5%−21.3
Q4 FY2024Dec 31, 2023-209.1%+86.4
Q3 FY2024Sep 30, 2023-249.6%+44.6
Q2 FY2024Jun 30, 2023-322.9%−48.6
Q1 FY2024Mar 31, 2023-315.2%−7.8
Q4 FY2023Dec 31, 2022-295.5%−147.3
Q3 FY2023Sep 30, 2022-294.2%−247.7
Q2 FY2023Jun 30, 2022-274.2%−209.6
Q1 FY2023Mar 31, 2022-307.5%−207.2
Q4 FY2022Dec 31, 2021-148.2%+84.3
Q3 FY2022Sep 30, 2021-46.5%−8.5
Q2 FY2022Jun 30, 2021-64.7%−16.9
Q1 FY2022Mar 31, 2021-100.3%−68.8
Q4 FY2021Dec 31, 2020-232.5%−172.2
Q3 FY2021Sep 30, 2020-38.0%+39.6
Q2 FY2021Jun 30, 2020-47.7%+34.0
Q1 FY2021Mar 31, 2020-31.5%+65.1
Q4 FY2020Dec 31, 2019-60.3%−48.9
Q3 FY2020Sep 30, 2019-77.6%+9.8
Q2 FY2020Jun 30, 2019-81.7%−29.6
Q1 FY2020Mar 31, 2019-96.6%−50.0
Q4 FY2019Dec 31, 2018-11.4%+24.6
Q3 FY2019Sep 30, 2018-87.4%−61.1
Q2 FY2019Jun 30, 2018-52.2%−17.1
Q1 FY2019Mar 31, 2018-46.6%−3.8
Q4 FY2018Dec 31, 2017-36.0%+12.8
Q3 FY2018Sep 30, 2017-26.3%+33.7
Q2 FY2018Jun 30, 2017-35.0%–
Q1 FY2018Mar 31, 2017-42.9%–
Q4 FY2017Dec 31, 2016-48.8%–
Q3 FY2017Sep 30, 2016-60.0%–

More Travere Therapeutics figures

See a number that looks wrong?